SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO )
CNTO 0.000010000.0%Mar 7 3:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Thean who wrote (33)11/11/1996 4:37:00 PM
From: Bob Ponko   of 965
 
I have now had a chance to look closely at the 6 month EPILOG data. The pieces are now in place to get FDA approval for REOPRO for all angioplasties. I would expect CNTO to move upwards in the next few months as:
1) The company files an expanded application with the FDA.
2) Cost effectiveness data from the EPILOG study demonstrate the cost benefit of REOPRO.
3) Efforts to expand approval to unstable angina and acute MI begin
CNTO has a high valuation now at 2.1 billion, but I am confident that as the years roll by the current stock price will look very cheap by comparison.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News